Sponsor(s):Institute of Chinese Pharmaceutical Association
24 issues per year
Journal official website:http://zgzye.cbpt.cnki.net/WKE/WebPublication/index.aspx?mid=zgzye
China Journal of Chinese Materia Medica, the 1st in the field of TCM, is supervised by China Association for Science and Technology and sponsored by Institute of Chinese Pharmaceutical Association. The journal is China's earliest comprehensive core journal of traditional Chinese medicine, and always maintains the circulation top in the professional areas. The journal publishes the latest research and progress of traditional Chinese medicine and takes a leading position in numbers of articles published, downloads and citations among all journals in this discipline. Its scope covers new achievements, technologies, methods, experiences and concepts resulting from the research on Chinese materia medica pursuant to Chinese medical and pharmaceutical theories, traditional experiences, and modern science and technology, including medicinal resources and identification, cultivation, processing, preparation, chemistry, pharmacology, theory of Chinese pharmacy and clinical practice, bencaological study. The journal is included in CA, JST and CSCD.
Zhang Boli, Hu Zhibi, Yao Xinsheng, Li Lianda, Li Dapeng, Yang Baofeng, Zhou Chaofan, Huang Luqi, Chen Shilin, Li He.
Executive Editorial Board
Cai Shaoqing, Chen Shilin, Cheng Yiyu, Du Lijun, Du Shouying, Du Zhimin, Gao Wenyuan, Guo Qiaosheng, Guo De’an, Hu Jingqing, Huang Luqi, Liu Hongning, Liu Jianxun, Lv Guiyuan, Qian Zhongzhi, Tu Pengfei, Wang Jie, Wang Zhengtao, Xiao Xiaohe, Yang Xiuwei, Ye Zhengliang, Yu Shishan, Zhang Boli, Zhang Weidong, Zhao Junning,, Zhong Guoyue, Wu hao, Zhu xiaoxin.
Bai Lixi, Bi Kaishun, Bian Baolin, Bian Ka, Cai Shaoqing, Che Zhentao, Chen Changxun, Chen Daofeng, Chen Hubiao, Chen Jijun, Chen Jiachun, Chen Ping, Chen Shilin, Chen Xiangmei, Cheng Yiyu, Cui Xiaolan, Dai Min, Ding Anwei, Du Guanhua, Du Guiyou, Du Lijun, Du Shouying, Du Zhimin, Duan Hongquan, Duan Jin’ao, Dou Qiling, Guo Baolin, Fan Xiaohui, Feng Jianfang, Feng Yi, Gao Weiwei, Gao Wenyuan, Gao Xiumei, Gao Yue, Gao Hao, Gu Jian, Guo Lanping, Guo Qiaosheng, Guo Shunxing, Guo Yujie, Guo Yuewei, Guo De’an, Hao Minghong, He Fuyuan, Hou Shixiang, Hu Jingqing, Hu Jun, Hu Zhibi, Huang Luqi, Huang Wenrong, Jia Tianzhu, Jia Xiaobin, Jiang Ye, Kang Wenyi, Kong Lingyi, Ku Baoshan, Lei Yan, Li Baoxin, Li Bo, Li Dapeng, Li He, Li Jianrong, Li Jiang, Li Lianda, Li Longyun, Li Ping, Li Shao, Li Shaoping, Li Shunxiang, Li Xuejun, Liang Aihua, Liang Rixin, Lin Na, Lin Pengcheng, Lin Ruichao, Lin Sheng, Lin Yaping, Liu Chenghai, Liu Hongning, Liu Jianxun, Liu Liang, Liu Ping, Liu Ping, Liu Xian, Liu Yong, Liu Zhen, Lv Guiyuan, Luo Xiaojian, Luo Yongming, Ma Changhua, Ma Kun, Ma Shuangcheng, Ma Xiaojun, Ma Xingtian, Mao Shengjun, Na Shengsang, Ni Jian, Peng Cheng, Peng Daiyin, Peng Jian, Peng Yong, Qian Zhongzhi, Qiao Shanyi, Qiao Yanjiang, Qin Hailin, Qin Luping, Qiu Minghua, Qu Haibin, Shi Jiangong, Shi Renbing, Shang Xiaoya, Si Jinping, Sun Rong, Sun Xiaobo, Tan Ninghua, Tan Rui, Tang Zhishu, Tang Xudong, Tu Pengfei, Wan Yigang, Wang Chang’en, Wang Jie, Wang Ruwei, Wang Shuoren, Wang Wenping, Wang Xijun, Wang Xiao, Wang Xuan, Wang Xuemei, Wang Yitao, Wang Yonglin, Wang Yongyan, Wang Yuesheng, Wang Zhengtao, Wang Zhibin, Wang Zhimin, Wang Zhong, Wei Lixin, Wu Chunfu, Wu Hao, Wu Lijun, Xiao Hongbin, Xiao Lin, Xiao Peigen, Xiao Wei, Xiao Xiaohe, Xiao Yongqing, Xie Ning, Xie Weidong, Xie Yanming, Xu Hongxi, Xu Qiang, Xu Ximing, Xue Jianping, Yan Dan, Yan Zhiyong, Yang Baofeng, Yang Bin, Yang Hua, Yang Hongjun, Yang Ming, Yang Xiuwei, Yao Xinsheng, Ye Wencai, Ye Zhengliang, Yu Rongmin, Yu Shishan, Zhang Boli, Zhang Qiwei, Zhang Ruixian, Zhang Weidong, Zhang Wensheng, Zhang Yongxiang, Zhang Yujie, Zhang Yunling, Zhao Junning, Zhao Xiaoping, Zhao Yuqing, Zhao Zhongzhen, Zheng Lu, Zhong Guoyue, Zhou Chaofan, Zhu Shengshan, Zhu Xiaoxin, Hiroshi Kurihara(JAP), Lai Shenghan(U.S.), Jia Wei(U.S.), Charlie Changli XUE(AUS), Hiroshi Saito(JAP), Rudolf Bauer(AUT), Peter J.Houfhton(ENG), Il-Moo CHANG(KOR), Tatyana L Kisseleva(RUS)
HPLC fingerprint and content determination of three principal components in seeds of Crataegus pinnatifida
China Journal of Chinese Materia Medica,2022,No. 11
The purpose of this paper is to establish the HPLC fingerprint and content determination method for Crataegus pinnatifida seeds. The separation was developed on a Welch Ultimate XB C18 column (4.6 mm × 250 mm, 5μm) by gradient elution with acetonitrile-water containing 0. 1% formic acid as the mobile phase at the flow rate of 1 mL·min-1, with the column temperature of 30℃, the injection volume of 10 μL, and the detection wavelength of 320 nm. Eighteen batches of samples were analyzed under the above chromatographic conditions to establish the fingerprint of C. pinnatifida seeds from different producing areas and a total of 24 common peaks were selected. The structures of three main chromatographic peaks were identified by comparison to reference substances, and the three compounds were simultaneously analyzed for content determination. They were identified as erythro-(7S,8R)-guaiacylglycerol-β-coniferyl aldehyde ether, threo-(7R,8R)-guaiacylglycerol-β-coniferyl aldehyde ether, and balanophonin, respectively. The relative similarity of fingerprints of 18 batches of samples and references ranged from 0.928 to 0.999, and the content of the three compounds was 0.055 1-0.182 7, 0.061 8-0.225 8, and 0.156 8-0.405 6 mg·g-1, respectively. SPSS 17.0 and SIMCA14.1 were used for cluster analysis, principal component analysis (PCA), and orthogonal partial least squares discriminant analysis (OPLS-DA) on the common peaks of the HPLC fingerprint of C. pinnatifida seeds. The results showed that there were significant differences between the two batches of samples from Liaoning province and the other samples, and the three compounds to be tested were the main components leading to the difference of C. pinnatifida seeds. The established method was simple and reliable and can be used for qualitative and quantitative analysis of C. pinnatifida seeds. The findings of this study are expected to provide a scientific basis for quality control of C. pinnatifida seeds.
Mechanism of Guanxinning against cerebral ischemia-reperfusion injury in mice based on transcriptomic analysis
China Journal of Chinese Materia Medica,2022,No. 11
Guanxinning, a modern Chinese medicine preparation composed of Salviae Miltiorrhizae Radix et Rhizoma and Chuanxiong Rhizoma, has the activities of activating blood circulation, resolving blood stasis, dredging vessels, and nourishing the heart. Clinical studies have demonstrated that Guanxinning has therapeutic effect on ischemic stroke, while the specific mechanism remains to be clarified. In this study, the potential mechanism of Guanxinning against cerebral ischemia-reperfusion injury in mice was explored and then verified in vitro. The mouse model of cerebral ischemia-reperfusion injury was established with middle cerebral artery occlusion (MCAO) method. The pharmacological effects of Guanxinning on the model mice were investigated based on neurological function score, cerebral infarction area, pathological morphology, neuron injury, and apoptosis. The results showed that Guanxinning lowered neurological functional score, reduced cerebral infarction area, and ameliorated the histopathological morphology, neuronal damage, and apoptosis in the model mice. RNA samples were extracted from brain tissues and subjected to RNA sequencing (RNAseq). The differentially expressed genes (DEGs) were screened with the thresholds of |log2FC| > 1 and P < 0.05. GO function enrichment analysis and KEGG pathway enrichment analysis were performed for the 297 common DEGs, which indicated that Guanxinning may regulate the inflammatory response, oxidative stress response, energy metabolism, and apoptosis to treat cerebral ischemia-reperfusion injury in mice. Guanxinning exerted protective effect through inhibiting inflammation and reducing oxidative stress in hypoxia/reoxygenation injured SH-SY5Y cells. Furthermore, Western blot indicated that Guanxinning down-regulated the protein levels of p-NF-κB p65 and p-p38 MAPK and up-regulated those of PPARγ and PGC-1α. The findings suggested that Guanxinning may inhibit inflammation and reduce oxidative stress by suppressing TNF signaling pathway and activating PPAR signaling pathway, thereby exerting the therapeutic effect on cerebral ischemia-reperfusion injury in mice. This study preliminarily reveals the mechanism of Guanxinning against cerebral ischemia-reperfusion injury and provides a basis for clinical application of Guanxinning.